Skip to Content

Pomalyst (pomalidomide) Disease Interactions

There are 7 disease interactions with Pomalyst (pomalidomide):

Major

Pomalidomide (Includes Pomalyst) ↔ Thromboembolic Events

Severe Potential Hazard, Moderate plausibility

Applies to: Thrombotic/Thromboembolic Disorder

Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboembolic events (myocardial infarction and stroke) have been observed in patients treated with pomalidomide. Exercise care when using this agent in patients with known risk factors, including prior thrombosis, as they might be at greater risk. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors.

Moderate

Pomalidomide (Includes Pomalyst) ↔ Hematologic Toxicities

Moderate Potential Hazard, Moderate plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

The use of pomalidomide has been associated with hematological toxicities, followed by anemia and thrombocytopenia. It is recommended to monitor patients for hematologic toxicities, especially neutropenia. Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter and depending on findings, patients may require dose interruption and/or modification. Close monitoring is recommended.

Moderate

Pomalidomide (Includes Pomalyst) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Pomalidomide is primarily metabolized in the liver by CYP450 1A2 and CYP450 3A4. Hepatic failure, including fatal cases, has occurred in patients treated with pomalidomide. Elevated levels of alanine aminotransferase and bilirubin have also been observed. Reduce the starting dose of pomalidomide by 25% (3 mg daily) in patients with mild to moderate hepatic impairment and by 50% (2 mg daily) in those patients with severe hepatic impairment. It is recommended to monitor liver function tests monthly and to stop treatment with pomalidomide upon elevation of liver enzymes. After return to baseline values, treatment at a lower dose may be considered.

Moderate

Pomalidomide (Includes Pomalyst) ↔ Neuropathy

Moderate Potential Hazard, Moderate plausibility

Applies to: Peripheral Neuropathy

The use of pomalidomide has been associated with the development of neuropathy. Therapy with pomalidomide should be administered cautiously in patients with or at risk for neuropathy. Monitor closely for signs and symptoms associated with neuropathy and evaluate patients accordingly.

Moderate

Pomalidomide (Includes Pomalyst) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: hemodialysis

Pomalidomide pharmacokinetic parameters were not significantly affected in patients with moderate or severe renal impairment. Pomalidomide should be used with caution in patients with severe renal impairment requiring dialysis and it should be administered after the completion of hemodialysis on dialysis days as the exposure of the drug could be significantly increased. Dose modification, 25% dose reduction (3 mg daily) is recommended at the start of therapy in patients with severe renal impairment requiring dialysis. Close monitoring is recommended.

Moderate

Pomalidomide (Includes Pomalyst) ↔ Smoking

Moderate Potential Hazard, Moderate plausibility

Applies to: Smoking

Cigarette smoking reduces pomalidomide AUC by 32% due to CYP450 1A2 induction. Advise patients that smoking may reduce the efficacy of pomalidomide.

Moderate

Pomalidomide (Includes Pomalyst) ↔ Tumor Lysis Syndrome

Moderate Potential Hazard, Moderate plausibility

Applies to: Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) may occur in patients receiving pomalidomide. Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS. Monitor for signs and symptoms of TLS. Temporary interruption or discontinuation of therapy might be required.

Pomalyst (pomalidomide) drug Interactions

There are 337 drug interactions with Pomalyst (pomalidomide)

Pomalyst (pomalidomide) alcohol/food Interactions

There is 1 alcohol/food interaction with Pomalyst (pomalidomide)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide